jumbo phages have unique
biological properties of high
potential to develop novel
technologies targeting top priority AMR pathogens
News & PRess
> nov '23
Nova awards winner
Uruguayan Innovation Awards: winners in the Startup Category
Kinzbio won the NOVA Award in the Startup category for its contributions to the field of antimicrobial research. Specifically recognized for their pioneering work in "Jumbo Phages for the Development of New Anti-bacterial Tools and Other Biomedical Applications".
The NOVA Awards by ANII aims to celebrate impactful initiatives, foster an innovative culture across diverse sectors, and highlight success stories that underscore Uruguay's capacity for innovation.
This acknowledgment serves as motivation, inspiring us to persist in our innovative pursuits for a better world. We firmly believe in the potential of our developments to solve one of the biggest global health issues that humanity is facing, the antimicrobial resistance pandemic. This recognition reinforces our commitment to bring solutions to people.
unleashing the potential of
Jumbo phages
together
Kinzbio fosters collaborations and partnerships with pharma leaders, clinical organizations, academic labs and funding agencies to help the company to accelerate the development of its jumbo phage platform and pipeline.
Kinzbio has an open communication channel with and is always seeking to hear from industry partners and funding institutions interested in joining efforts to keep developing applications based on the biology of jumbo phages.
BE IN
TOUCH
Please fill your contact details below:
Phage technologies for a
healthier world
ANtimicrobial
resistance is one
of the major global
health issues that
humanity is facing
every year millions
of lives are lost and
billions are spent in
prevention and
treatment of AMR
phages are natural
bacterial killers
that can be used to
combat AMR pathogens
